{"protocolSection": {"identificationModule": {"nctId": "NCT03063086", "orgStudyIdInfo": {"id": "CQVM149B2208"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.", "officialTitle": "A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma"}, "statusModule": {"statusVerifiedDate": "2021-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-01-21", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-08-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-08-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-02-21", "studyFirstSubmitQcDate": "2017-02-21", "studyFirstPostDateStruct": {"date": "2017-02-24", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2019-07-31", "resultsFirstSubmitQcDate": "2019-11-25", "resultsFirstPostDateStruct": {"date": "2019-12-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-09-30", "lastUpdatePostDateStruct": {"date": "2021-10-04", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess peak FEV1 of two doses of QVM149 compared to a fixed-dose combination of salmeterol/fluticasone (50/500\u03bcg b.i.d.) and to characterize the respective 24 hour bronchodilator effect profiles in patients with asthma. Data from this study will complement lung function data obtained in the pivotal QVM149 phase 3 program by assessing the bronchodilatory effect of QVM149 at multiple time-points over an entire dosing interval of 24 hours."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 116, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sequence 1", "type": "ACTIVE_COMPARATOR", "description": "A-B-C", "interventionNames": ["Drug: QVM149 150/50/80 \u03bcg o.d.", "Drug: QVM149 150/50/160 \u03bcg o.d.", "Drug: salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d."]}, {"label": "Sequence 2", "type": "ACTIVE_COMPARATOR", "description": "A-C-B", "interventionNames": ["Drug: QVM149 150/50/80 \u03bcg o.d.", "Drug: QVM149 150/50/160 \u03bcg o.d.", "Drug: salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d."]}, {"label": "Sequence 3", "type": "ACTIVE_COMPARATOR", "description": "B-C-A", "interventionNames": ["Drug: QVM149 150/50/80 \u03bcg o.d.", "Drug: QVM149 150/50/160 \u03bcg o.d.", "Drug: salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d."]}, {"label": "Sequence 4", "type": "ACTIVE_COMPARATOR", "description": "B-A-C", "interventionNames": ["Drug: QVM149 150/50/80 \u03bcg o.d.", "Drug: QVM149 150/50/160 \u03bcg o.d.", "Drug: salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d."]}, {"label": "Sequence 5", "type": "ACTIVE_COMPARATOR", "description": "C-A-B", "interventionNames": ["Drug: QVM149 150/50/80 \u03bcg o.d.", "Drug: QVM149 150/50/160 \u03bcg o.d.", "Drug: salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d."]}, {"label": "Sequence 6", "type": "ACTIVE_COMPARATOR", "description": "C-B-A", "interventionNames": ["Drug: QVM149 150/50/80 \u03bcg o.d.", "Drug: QVM149 150/50/160 \u03bcg o.d.", "Drug: salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d."]}], "interventions": [{"type": "DRUG", "name": "QVM149 150/50/80 \u03bcg o.d.", "description": "A", "armGroupLabels": ["Sequence 1", "Sequence 2", "Sequence 3", "Sequence 4", "Sequence 5", "Sequence 6"]}, {"type": "DRUG", "name": "QVM149 150/50/160 \u03bcg o.d.", "description": "B", "armGroupLabels": ["Sequence 1", "Sequence 2", "Sequence 3", "Sequence 4", "Sequence 5", "Sequence 6"]}, {"type": "DRUG", "name": "salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d.", "description": "C", "armGroupLabels": ["Sequence 1", "Sequence 2", "Sequence 3", "Sequence 4", "Sequence 5", "Sequence 6"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period", "description": "The highest bronchodilator effect on FEV1 during a period of 5 min to 4 h after the last evening dose of each treatment period . To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 \u03bcg o.d. and 150/50/80 \u03bcg o.d. compared to a FDC of salmeterol/fluticasone at a dose of 50/500 \u03bcg b.i.d. after 3 weeks of treatment in patients with asthma", "timeFrame": "3 weeks"}], "secondaryOutcomes": [{"measure": "FEV1 Over 24 h After 21 Days of Treatment in Relation to Evening Dose", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.", "timeFrame": "-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks"}, {"measure": "FVC Over 24 h After 21 Days of Treatment in Relation to Evening Dose", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.", "timeFrame": "-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks"}, {"measure": "FEV1/FVC Ratio Over 24 h After 21 Days of Treatment in Relation to Evening Dose", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.", "timeFrame": "-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks"}, {"measure": "FEV1 AUC 5 Min - 1 h (Day 21) FEV1 AUC 5 Min - 4 h (Day 21) and FEV1 AUC 5 Min - 23 h 45 Min (Day 21)", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/ fluticasone FDC by measuring standardized FEV1 AUCs after 3 weeks of treatment respective period.", "timeFrame": "3 weeks"}, {"measure": "Trough FEV1 After 21 Days of Treatment", "description": "To evaluate post-dose trough bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment in the respective treatment period. The trough FEV1 is the mean value of FEV1 at 23 h 15 min and 23 h 45 min post-dose", "timeFrame": "3 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion criteria\n\n* Male and female adult patients \u2265 18 years old and \u2264 75 years.\n* Patients with a documented physician diagnosis of asthma for a period of at least 12 months prior to Visit 1 (Screening).\n* Patients who have used ICS and LABA combinations for asthma for at least 3 month and at a stable medium or high dose of ICS for at least 1 month prior to Visit 1 (Screening).\n* Pre-bronchodilator FEV1 of \\< 80 % of the predicted normal value at screening Visit 1 (spirometry will not be repeated at baseline prior to randomization).\n* Patients who demonstrate an increase in FEV1 of \u2265 12 % and 200 mL after administration of 400 \u00b5g salbutamol/360 \u00b5g albuterol (or equivalent do se) at Visit 1 (Screening). All patients must perform a reversibility test at Visit 1 (Screening). If reversibility is not demonstrated at Visit 1 (Screening), then, reversibility testing may be repeated once during the screening period.\n* If reversibility is not demonstrated at Visit 1 (retesting allowed once), patients must be screen failed. Spacer devices are not permitted during reversibility testing Key Exclusion criteria\n* Patients who have smoked or inhaled tobacco products within the 6 month period prior to Visit 1\n* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1\n* Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention\n* Patients who have had a respiratory tract infection or asthma worsening within 4 weeks prior to Visit 1\n* Patients with any chronic conditions affecting the upper respiratory tract\n* Patients with a history of chronic lung diseases other than asthma, including (but not limited to) COPD, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.\n* Patients with Type I diabetes or uncontrolled Type II diabetes (HbA1c \\>9% at screening).\n* Patients who have a clinically significant ECG abnormality at Visit 1\n* Patients with a history of hypersensitivity or intolerance to any of the study drugs (including excipients)\n* Patients with narcolepsy and/or insomnia.\n* Patients on Maintenance Immunotherapy (desensitization) for allergies for less than 3 months prior to Visit 2 or patients on Maintenance Immunotherapy for more than 3 months prior to Visit 2 but expected to change throughout the course of the study.\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential must use Highly effective contraception methods\n* Patients who have discontinued LAMA therapy in the past for any safety, tolerability or perceived lack of efficacy reason.\n* History of paradoxical bronchospasm in response to inhaled medicines.\n* Patients with a history of clinically relevant bronchoconstriction upon repeated forced expiratory maneuvers.\n* Patient with a serum potassium level below the laboratory limit of normal at screening.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Novartis Investigative Site", "city": "Sofia", "zip": "1612", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"facility": "Novartis Investigative Site", "city": "Chang Chun", "state": "Jilin", "zip": "130021", "country": "China", "geoPoint": {"lat": 42.74694, "lon": 126.24667}}, {"facility": "Novartis Investigative Site", "city": "Tianjin", "state": "Tianjin", "zip": "300192", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novartis Investigative Site", "city": "Shanghai", "zip": "200433", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Grosshansdorf", "zip": "22947", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Novartis Investigative Site", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Novartis Investigative Site", "city": "Wiesbaden", "zip": "65187", "country": "Germany", "geoPoint": {"lat": 50.08258, "lon": 8.24932}}, {"facility": "Novartis Investigative Site", "city": "Groningen", "state": "GZ", "zip": "9713", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Manchester", "zip": "M23 9QZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "A Plain Language Trial Summary is available on novartisclinicaltrials.com", "url": "https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=392"}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Sequence 1 (A-B-C)", "description": "QVM149 150/50/80 \u03bcg o.d; QVM149 150/50/160 \u03bcg o.d; salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d."}, {"id": "FG001", "title": "Sequence 2(A-C-B)", "description": "QVM149 150/50/80 \u03bcg o.d; salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d.; QVM149 150/50/160 \u03bcg o.d;"}, {"id": "FG002", "title": "Sequence 3(B-C-A)", "description": "QVM149 150/50/160 \u03bcg o.d; salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d.; QVM149 150/50/80 \u03bcg o.d"}, {"id": "FG003", "title": "Sequence 4(B-A-C)", "description": "QVM149 150/50/160 \u03bcg o.d; QVM149 150/50/80 \u03bcg o.d; salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d"}, {"id": "FG004", "title": "Sequence 5(C-A-B)", "description": "salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d; QVM149 150/50/80 \u03bcg o.d; QVM149 150/50/160 \u03bcg o.d"}, {"id": "FG005", "title": "Sequence 6(C-B-A)", "description": "salmeterol/fluticasone FDC 50/500 \u03bcg b.i.d.; QVM149 150/50/160 \u03bcg o.d; QVM149 150/50/80 \u03bcg o.d"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "18"}, {"groupId": "FG003", "numSubjects": "20"}, {"groupId": "FG004", "numSubjects": "20"}, {"groupId": "FG005", "numSubjects": "19"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "17"}, {"groupId": "FG003", "numSubjects": "17"}, {"groupId": "FG004", "numSubjects": "20"}, {"groupId": "FG005", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "technical problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "subject/guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Non-compliance with study treatment", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "All participants randomized to one of six treatment sequences"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "116"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.5", "spread": "14"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "55"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "61"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "106"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period", "description": "The highest bronchodilator effect on FEV1 during a period of 5 min to 4 h after the last evening dose of each treatment period . To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 \u03bcg o.d. and 150/50/80 \u03bcg o.d. compared to a FDC of salmeterol/fluticasone at a dose of 50/500 \u03bcg b.i.d. after 3 weeks of treatment in patients with asthma", "populationDescription": "Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "3 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u03bcg o.d.", "description": "QVM149 150/50/160 \u03bcg o.d."}, {"id": "OG001", "title": "QVM149 150/50/80 \u03bcg o.d.", "description": "QVM149 150/50/80 \u03bcg o.d."}, {"id": "OG002", "title": "Salmeterol/Fluticasone 50/500 \u00b5g b.i.d", "description": "salmeterol/fluticasone 50/500 \u00b5g b.i.d"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.792", "spread": "0.0750"}, {"groupId": "OG001", "value": "2.779", "spread": "0.0750"}, {"groupId": "OG002", "value": "2.620", "spread": "0.0750"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.172", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.137", "ciUpperLimit": "0.208"}, {"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Median Difference (Final Values)", "paramValue": "0.159", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.123", "ciUpperLimit": "0.195"}]}, {"type": "SECONDARY", "title": "FEV1 Over 24 h After 21 Days of Treatment in Relation to Evening Dose", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.", "populationDescription": "Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u03bcg o.d.", "description": "QVM149 150/50/160 \u03bcg o.d."}, {"id": "OG001", "title": "QVM149 150/50/80 \u03bcg o.d.", "description": "QVM149 150/50/80 \u03bcg o.d."}, {"id": "OG002", "title": "Salmeterol/Fluticasone 50/500 \u00b5g b.i.d", "description": "salmeterol/fluticasone 50/500 \u00b5g b.i.d"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"title": "-45 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "111"}, {"groupId": "OG002", "value": "111"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6237", "spread": "0.07505"}, {"groupId": "OG001", "value": "2.5639", "spread": "0.07503"}, {"groupId": "OG002", "value": "2.4931", "spread": "0.07505"}]}]}, {"title": "-15 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "109"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6023", "spread": "0.07479"}, {"groupId": "OG001", "value": "2.5630", "spread": "0.07478"}, {"groupId": "OG002", "value": "2.4835", "spread": "0.07480"}]}]}, {"title": "5 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "108"}, {"groupId": "OG002", "value": "109"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6412", "spread": "0.07446"}, {"groupId": "OG001", "value": "2.6179", "spread": "0.07445"}, {"groupId": "OG002", "value": "2.5035", "spread": "0.07446"}]}]}, {"title": "15 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "108"}, {"groupId": "OG002", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6696", "spread": "0.07531"}, {"groupId": "OG001", "value": "2.6137", "spread": "0.07532"}, {"groupId": "OG002", "value": "2.5172", "spread": "0.07533"}]}]}, {"title": "30 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "108"}, {"groupId": "OG002", "value": "110"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6873", "spread": "0.07444"}, {"groupId": "OG001", "value": "2.6504", "spread": "0.07444"}, {"groupId": "OG002", "value": "2.5286", "spread": "0.07444"}]}]}, {"title": "1 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6922", "spread": "0.07430"}, {"groupId": "OG001", "value": "2.6825", "spread": "0.07431"}, {"groupId": "OG002", "value": "2.5398", "spread": "0.07431"}]}]}, {"title": "2 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "107"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7033", "spread": "0.07441"}, {"groupId": "OG001", "value": "2.6996", "spread": "0.07443"}, {"groupId": "OG002", "value": "2.5244", "spread": "0.07443"}]}]}, {"title": "3 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "106"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6995", "spread": "0.07449"}, {"groupId": "OG001", "value": "2.6719", "spread": "0.07450"}, {"groupId": "OG002", "value": "2.5296", "spread": "0.07451"}]}]}, {"title": "4 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "106"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6815", "spread": "0.07482"}, {"groupId": "OG001", "value": "2.6565", "spread": "0.07484"}, {"groupId": "OG002", "value": "2.5164", "spread": "0.07485"}]}]}, {"title": "8 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "104"}, {"groupId": "OG002", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6801", "spread": "0.07454"}, {"groupId": "OG001", "value": "2.6550", "spread": "0.07459"}, {"groupId": "OG002", "value": "2.4918", "spread": "0.07459"}]}]}, {"title": "10 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "105"}, {"groupId": "OG002", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6999", "spread": "0.07489"}, {"groupId": "OG001", "value": "2.6796", "spread": "0.07494"}, {"groupId": "OG002", "value": "2.4908", "spread": "0.07495"}]}]}, {"title": "11h 55 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "104"}, {"groupId": "OG002", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.7042", "spread": "0.07486"}, {"groupId": "OG001", "value": "2.6641", "spread": "0.07490"}, {"groupId": "OG002", "value": "2.4841", "spread": "0.07491"}]}]}, {"title": "14 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6829", "spread": "0.07456"}, {"groupId": "OG001", "value": "2.6541", "spread": "0.07459"}, {"groupId": "OG002", "value": "2.5354", "spread": "0.07461"}]}]}, {"title": "18 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}, {"groupId": "OG002", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6345", "spread": "0.07451"}, {"groupId": "OG001", "value": "2.6073", "spread": "0.07455"}, {"groupId": "OG002", "value": "2.5329", "spread": "0.07457"}]}]}, {"title": "21 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}, {"groupId": "OG002", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6113", "spread": "0.07466"}, {"groupId": "OG001", "value": "2.5989", "spread": "0.07472"}, {"groupId": "OG002", "value": "2.5133", "spread": "0.07475"}]}]}, {"title": "23 h 15 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "100"}, {"groupId": "OG002", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.6143", "spread": "0.07433"}, {"groupId": "OG001", "value": "2.5950", "spread": "0.07438"}, {"groupId": "OG002", "value": "2.4854", "spread": "0.07439"}]}]}, {"title": "23 h 45 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.5966", "spread": "0.07433"}, {"groupId": "OG001", "value": "2.5722", "spread": "0.07438"}, {"groupId": "OG002", "value": "2.4913", "spread": "0.07439"}]}]}]}, {"type": "SECONDARY", "title": "FVC Over 24 h After 21 Days of Treatment in Relation to Evening Dose", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.", "populationDescription": "Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u03bcg o.d.", "description": "QVM149 150/50/160 \u03bcg o.d."}, {"id": "OG001", "title": "QVM149 150/50/80 \u03bcg o.d.", "description": "QVM149 150/50/80 \u03bcg o.d."}, {"id": "OG002", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d", "description": "Salmeterol/fluticasone 50/500 \u03bcg b.i.d"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"title": "-45min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "110"}, {"groupId": "OG002", "value": "110"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9046", "spread": "1.03169"}, {"groupId": "OG001", "value": "3.8538", "spread": "0.98086"}, {"groupId": "OG002", "value": "3.7626", "spread": "1.00067"}]}]}, {"title": "-15min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "109"}, {"groupId": "OG002", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8743", "spread": "1.04318"}, {"groupId": "OG001", "value": "3.8571", "spread": "0.97420"}, {"groupId": "OG002", "value": "3.7230", "spread": "0.94180"}]}]}, {"title": "5min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "107"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8656", "spread": "0.99877"}, {"groupId": "OG001", "value": "3.8976", "spread": "1.00323"}, {"groupId": "OG002", "value": "3.7536", "spread": "0.93696"}]}]}, {"title": "15min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "106"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8669", "spread": "0.98489"}, {"groupId": "OG001", "value": "3.8971", "spread": "0.96840"}, {"groupId": "OG002", "value": "3.7290", "spread": "0.94033"}]}]}, {"title": "30min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "108"}, {"groupId": "OG002", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8700", "spread": "0.99289"}, {"groupId": "OG001", "value": "3.9002", "spread": "0.99091"}, {"groupId": "OG002", "value": "3.7695", "spread": "0.96026"}]}]}, {"title": "1h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "107"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8756", "spread": "0.99978"}, {"groupId": "OG001", "value": "3.8993", "spread": "0.99141"}, {"groupId": "OG002", "value": "3.7530", "spread": "0.97083"}]}]}, {"title": "2h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "107"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8698", "spread": "0.99623"}, {"groupId": "OG001", "value": "3.8985", "spread": "0.99369"}, {"groupId": "OG002", "value": "3.7629", "spread": "0.97164"}]}]}, {"title": "3h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8576", "spread": "0.98598"}, {"groupId": "OG001", "value": "3.8766", "spread": "0.97806"}, {"groupId": "OG002", "value": "3.7575", "spread": "0.96899"}]}]}, {"title": "4h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "106"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8744", "spread": "0.99833"}, {"groupId": "OG001", "value": "3.8627", "spread": "0.95673"}, {"groupId": "OG002", "value": "3.7629", "spread": "0.98205"}]}]}, {"title": "8h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9020", "spread": "0.98241"}, {"groupId": "OG001", "value": "3.9217", "spread": "0.99184"}, {"groupId": "OG002", "value": "3.7683", "spread": "1.00410"}]}]}, {"title": "10h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8976", "spread": "0.98360"}, {"groupId": "OG001", "value": "3.9504", "spread": "0.99286"}, {"groupId": "OG002", "value": "3.7809", "spread": "0.98213"}]}]}, {"title": "11h 55min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}, {"groupId": "OG002", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9271", "spread": "0.98924"}, {"groupId": "OG001", "value": "3.9405", "spread": "1.00198"}, {"groupId": "OG002", "value": "3.7911", "spread": "0.99102"}]}]}, {"title": "14h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.9091", "spread": "1.00241"}, {"groupId": "OG001", "value": "3.9210", "spread": "0.97942"}, {"groupId": "OG002", "value": "3.8089", "spread": "1.02918"}]}]}, {"title": "18h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}, {"groupId": "OG002", "value": "101"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8675", "spread": "0.95725"}, {"groupId": "OG001", "value": "3.9151", "spread": "1.02198"}, {"groupId": "OG002", "value": "3.7824", "spread": "0.98395"}]}]}, {"title": "21h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8438", "spread": "1.00672"}, {"groupId": "OG001", "value": "3.8694", "spread": "0.98786"}, {"groupId": "OG002", "value": "3.7680", "spread": "1.00768"}]}]}, {"title": "23h 15min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "100"}, {"groupId": "OG002", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.7997", "spread": "0.97550"}, {"groupId": "OG001", "value": "3.8673", "spread": "0.99915"}, {"groupId": "OG002", "value": "3.7395", "spread": "1.01764"}]}]}, {"title": "23h 45min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8034", "spread": "0.99036"}, {"groupId": "OG001", "value": "3.8603", "spread": "0.98502"}, {"groupId": "OG002", "value": "3.7431", "spread": "1.00668"}]}]}]}, {"type": "SECONDARY", "title": "FEV1/FVC Ratio Over 24 h After 21 Days of Treatment in Relation to Evening Dose", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.", "populationDescription": "Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u03bcg o.d.", "description": "QVM149 150/50/160 \u03bcg o.d."}, {"id": "OG001", "title": "QVM149 150/50/80 \u03bcg o.d.", "description": "QVM149 150/50/80 \u03bcg o.d."}, {"id": "OG002", "title": "Salmeterol/Fluticasone 50/500 \u03bcg b.i.d", "description": "Salmeterol/fluticasone 50/500 \u03bcg b.i.d"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"title": "-45min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6701", "spread": "0.10880"}, {"groupId": "OG001", "value": "0.6612", "spread": "0.10358"}, {"groupId": "OG002", "value": "0.6527", "spread": "0.10867"}]}]}, {"title": "-15min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6707", "spread": "0.10646"}, {"groupId": "OG001", "value": "0.6669", "spread": "0.10422"}, {"groupId": "OG002", "value": "0.6539", "spread": "0.10526"}]}]}, {"title": "5min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6788", "spread": "0.10300"}, {"groupId": "OG001", "value": "0.6754", "spread": "0.10370"}, {"groupId": "OG002", "value": "0.6563", "spread": "0.10639"}]}]}, {"title": "15min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6873", "spread": "0.10126"}, {"groupId": "OG001", "value": "0.6778", "spread": "0.10734"}, {"groupId": "OG002", "value": "0.6560", "spread": "0.10823"}]}]}, {"title": "30min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "108"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6878", "spread": "0.10137"}, {"groupId": "OG001", "value": "0.6844", "spread": "0.10699"}, {"groupId": "OG002", "value": "0.6573", "spread": "0.10552"}]}]}, {"title": "1h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6900", "spread": "0.09764"}, {"groupId": "OG001", "value": "0.6895", "spread": "0.09940"}, {"groupId": "OG002", "value": "0.6632", "spread": "0.10403"}]}]}, {"title": "2h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "105"}, {"groupId": "OG002", "value": "106"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6939", "spread": "0.09629"}, {"groupId": "OG001", "value": "0.6932", "spread": "0.10073"}, {"groupId": "OG002", "value": "0.6647", "spread": "0.10413"}]}]}, {"title": "3h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "106"}, {"groupId": "OG002", "value": "104"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6968", "spread": "0.10159"}, {"groupId": "OG001", "value": "0.6890", "spread": "0.10052"}, {"groupId": "OG002", "value": "0.6634", "spread": "0.10436"}]}]}, {"title": "4h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "107"}, {"groupId": "OG002", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6897", "spread": "0.10060"}, {"groupId": "OG001", "value": "0.6879", "spread": "0.09733"}, {"groupId": "OG002", "value": "0.6605", "spread": "0.10419"}]}]}, {"title": "8h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "95"}, {"groupId": "OG002", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6842", "spread": "0.10782"}, {"groupId": "OG001", "value": "0.6802", "spread": "0.11349"}, {"groupId": "OG002", "value": "0.6492", "spread": "0.10814"}]}]}, {"title": "10h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "104"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6916", "spread": "0.10550"}, {"groupId": "OG001", "value": "0.6858", "spread": "0.10468"}, {"groupId": "OG002", "value": "0.6489", "spread": "0.11155"}]}]}, {"title": "11h 55min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6853", "spread": "0.10672"}, {"groupId": "OG001", "value": "0.6791", "spread": "0.10656"}, {"groupId": "OG002", "value": "0.6482", "spread": "0.10810"}]}]}, {"title": "14h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "101"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6846", "spread": "0.10842"}, {"groupId": "OG001", "value": "0.6848", "spread": "0.10450"}, {"groupId": "OG002", "value": "0.6567", "spread": "0.11048"}]}]}, {"title": "18h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "101"}, {"groupId": "OG002", "value": "97"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6801", "spread": "0.09943"}, {"groupId": "OG001", "value": "0.6741", "spread": "0.10240"}, {"groupId": "OG002", "value": "0.6546", "spread": "0.10369"}]}]}, {"title": "21h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "99"}, {"groupId": "OG002", "value": "99"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6790", "spread": "0.10890"}, {"groupId": "OG001", "value": "0.6785", "spread": "0.10387"}, {"groupId": "OG002", "value": "0.6562", "spread": "0.10729"}]}]}, {"title": "23h 15min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "102"}, {"groupId": "OG001", "value": "98"}, {"groupId": "OG002", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "06821", "spread": "0.10386"}, {"groupId": "OG001", "value": "0.6791", "spread": "0.09986"}, {"groupId": "OG002", "value": "0.6548", "spread": "0.10423"}]}]}, {"title": "23h 45min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "98"}, {"groupId": "OG002", "value": "98"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6782", "spread": "0.10457"}, {"groupId": "OG001", "value": "0.6776", "spread": "0.10111"}, {"groupId": "OG002", "value": "0.6537", "spread": "0.10934"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 AUC 5 Min - 1 h (Day 21) FEV1 AUC 5 Min - 4 h (Day 21) and FEV1 AUC 5 Min - 23 h 45 Min (Day 21)", "description": "To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/ fluticasone FDC by measuring standardized FEV1 AUCs after 3 weeks of treatment respective period.", "populationDescription": "Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "3 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u03bcg o.d.", "description": "QVM149 150/50/160 \u03bcg o.d."}, {"id": "OG001", "title": "QVM149 150/50/80 \u03bcg o.d.", "description": "QVM149 150/50/80 \u03bcg o.d."}, {"id": "OG002", "title": "Salmeterol/Fluticasone 50/500 \u00b5g b.i.d", "description": "salmeterol/fluticasone 50/500 \u00b5g b.i.d"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"title": "FEV1 AUC 5 min - 1 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "103"}, {"groupId": "OG002", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.673", "spread": "0.0735"}, {"groupId": "OG001", "value": "2.644", "spread": "0.0736"}, {"groupId": "OG002", "value": "2.513", "spread": "0.0737"}]}]}, {"title": "FEV1 AUC 5 min - 4 h", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "104"}, {"groupId": "OG002", "value": "99"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.687", "spread": "0.0741"}, {"groupId": "OG001", "value": "2.669", "spread": "0.0741"}, {"groupId": "OG002", "value": "2.510", "spread": "0.0742"}]}]}, {"title": "FEV1 AUC 5 min - 23 h 45 min", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "93"}, {"groupId": "OG002", "value": "92"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.677", "spread": "0.0766"}, {"groupId": "OG001", "value": "2.652", "spread": "0.0768"}, {"groupId": "OG002", "value": "2.515", "spread": "0.0768"}]}]}]}, {"type": "SECONDARY", "title": "Trough FEV1 After 21 Days of Treatment", "description": "To evaluate post-dose trough bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment in the respective treatment period. The trough FEV1 is the mean value of FEV1 at 23 h 15 min and 23 h 45 min post-dose", "populationDescription": "Pharmacodynamics set - The PD analysis set included all patients with any available PD data, who received any study treatment and experienced no protocol deviations with relevant impact on PD data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "3 weeks", "groups": [{"id": "OG000", "title": "QVM149 150/50/160 \u03bcg o.d.", "description": "QVM149 150/50/160 \u03bcg o.d."}, {"id": "OG001", "title": "QVM149 150/50/80 \u03bcg o.d.", "description": "QVM149 150/50/80 \u03bcg o.d."}, {"id": "OG002", "title": "Salmeterol/Fluticasone 50/500 \u00b5g b.i.d", "description": "salmeterol/fluticasone 50/500 \u00b5g b.i.d"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "115"}, {"groupId": "OG002", "value": "111"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.623", "spread": "0.0756"}, {"groupId": "OG001", "value": "2.6046", "spread": "0.0757"}, {"groupId": "OG002", "value": "2.4998", "spread": "0.0757"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.124", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.086", "ciUpperLimit": "0.161"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Up to 22 days", "eventGroups": [{"id": "EG000", "title": "QVM149 150/50/160 \u00b5g o.d.", "description": "QVM149 150/50/160 \u00b5g o.d.", "deathsNumAffected": 0, "deathsNumAtRisk": 112, "seriousNumAffected": 0, "seriousNumAtRisk": 112, "otherNumAffected": 14, "otherNumAtRisk": 112}, {"id": "EG001", "title": "QVM149 150/50/80 \u00b5g o.d.", "description": "QVM149 150/50/80 \u00b5g o.d.", "deathsNumAffected": 0, "deathsNumAtRisk": 115, "seriousNumAffected": 0, "seriousNumAtRisk": 115, "otherNumAffected": 18, "otherNumAtRisk": 115}, {"id": "EG002", "title": "Salmeterol/Fluticasone 50/500 \u00b5g b.i.d.", "description": "Salmeterol/fluticasone 50/500 \u00b5g b.i.d.", "deathsNumAffected": 0, "deathsNumAtRisk": 111, "seriousNumAffected": 0, "seriousNumAtRisk": 111, "otherNumAffected": 21, "otherNumAtRisk": 111}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 111}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 111}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 111}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (21.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 112}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 115}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 111}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety"}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-01-12", "uploadDate": "2019-07-31T08:48", "filename": "Prot_001.pdf", "size": 4279525}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-09-06", "uploadDate": "2019-07-31T08:48", "filename": "SAP_000.pdf", "size": 1302317}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}